Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $7.50

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.75.

Several equities analysts recently issued reports on the company. Weiss Ratings downgraded Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wedbush lifted their price target on Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Leerink Partners dropped their price target on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, July 2nd. Wells Fargo & Company increased their price objective on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Finally, HC Wainwright raised their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in shares of Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares during the last quarter. J. Derek Lewis & Associates Inc. purchased a new position in shares of Pyxis Oncology during the fourth quarter worth $61,000. 683 Capital Management LLC raised its holdings in shares of Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock worth $1,026,000 after purchasing an additional 366,910 shares during the last quarter. Finally, Atle Fund Management AB acquired a new position in Pyxis Oncology during the fourth quarter valued at $710,000. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Trading Down 2.9%

NASDAQ:PYXS opened at $3.33 on Wednesday. The company has a market cap of $277.76 million, a PE ratio of -2.36 and a beta of 1.34. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55. The company’s 50 day moving average is $3.06 and its two-hundred day moving average is $2.27.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). As a group, analysts expect that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company’s approach is centered on creating antibody-based medicines designed to selectively target tumor cells or the tumor microenvironment while delivering therapeutic activity intended to improve cancer treatment outcomes.

Pyxis Oncology’s pipeline has included PYX-201, an antibody-drug conjugate designed to target extra-domain B fibronectin, a protein associated with the tumor microenvironment, and PYX-106, an investigational antibody targeting SIGLEC-15, an immune-regulatory protein expressed in several cancers.